Dual Agonist

Deep dive

Dual Agonist: complete reference

A dual agonist is a pharmaceutical agent that simultaneously activates two distinct receptor types. Tirzepatide (Mounjaro, Zepbound) is the first FDA-approved dual agonist in the GLP-1 class, activating both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual mechanism is believed to drive its superior weight-loss outcomes vs single-receptor GLP-1 agonists: 22.5% weight loss in SURMOUNT-1 (tirzepatide 15mg) vs 14.9% in STEP-1 (semaglutide 2.4mg). The exact contribution of GIP receptor activation is still being characterized — proposed mechanisms include effects on adipose tissue lipid handling, central nervous system appetite regulation, and synergy with GLP-1 signaling. Triple agonists (GLP-1 + GIP + glucagon, like retatrutide) are in Phase 3 trials and have shown even higher weight loss potential in early data (~24% in Phase 2). The dual/triple-agonist class represents the cutting edge of obesity pharmacotherapy as of 2026.

In practice

When you take Zepbound, the molecule activates BOTH the GLP-1 receptor (familiar from Wegovy) AND the GIP receptor — this dual activation is what makes tirzepatide more effective than semaglutide on average.

Clinical context

Tirzepatide is the only FDA-approved dual GIP/GLP-1 agonist as of 2026. Triple agonists (retatrutide) in Phase 3.